Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study. - Wikidata - wikimedia - TriplyDB

Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study.

Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study.

http://www.wikidata.org/entity/Q38409715

about

Mechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary Immunodeficiencies Expanding Role of T Cells in Human Autoimmune Diseases of the Central Nervous System.Anti-LGI1 encephalitis is associated with unique HLA subtypes.Innate and adaptive immunity in human epilepsies.Cerebrospinal fluid cyto-/chemokine profile during acute herpes simplex virus induced anti-N-methyl-d-aspartate receptor encephalitis and in chronic neurological sequelae.Interleukin-6 Blockade as Rescue Therapy in Autoimmune Encephalitis.Extra-central nervous system target for assessment and treatment in refractory anti-N-methyl-d-aspartate receptor encephalitis.High albumin level is a predictor of favorable response to immunotherapy in autoimmune encephalitis.Treatment strategies for autoimmune encephalitis.[Update on anti-N-methyl-D-aspartate receptor encephalitis].Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.Bortezomib treatment for severe refractory anti-NMDA receptor encephalitis.The clinical features, underlying immunology, and treatment of autoantibody-mediated movement disorders

P2860

Q28066193-A5AC7907-A43D-4A9E-85E4-8C6F3A01036F Q33770508-4DA32FE2-704C-4AE4-8678-FAE1070116CF Q38407241-6E0E18A3-771B-4FF2-AF5E-0156A6E27178 Q40135696-CD3DED1B-C537-43F5-ACD4-1A94E604A6AD Q40229229-DBD91C1F-612E-45EE-A293-5787CC60026D Q42379836-E6821038-28F3-4516-ADE0-36B146552C17 Q48475018-E25B5508-84B4-466A-B789-8DE8B01B3843 Q49165786-B5698F87-BCCA-486B-8D96-37221ACC315D Q49213573-ED65ABE8-1D9E-4DF3-99F6-92D6E86D3446 Q49971610-8437E8BE-9956-459D-83BE-ACDEF2D576CE Q55052878-67345442-9FD2-45F5-AE36-D16C15140958 Q55407957-9A68FDBE-606A-47F3-9ADC-8DA661CFFD26 Q57157350-A9243129-4515-419B-B742-C697C15A2A78

P2860

Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study.

http://www.wikidata.org/entity/Q38409715

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Tocilizumab in Autoimmune Ence ...... An Institutional Cohort Study.

@en

type

label

Tocilizumab in Autoimmune Ence ...... An Institutional Cohort Study.

@en

prefLabel

Tocilizumab in Autoimmune Ence ...... An Institutional Cohort Study.

@en

P1433

Q38409715-72901465-E6A9-41CE-B0B2-E6F5847D2493

P1476

Q38409715-725C0782-EC03-4B5A-8CA2-6CB8460D0A18

P2093

Q38409715-09479366-6437-4658-9A57-4B410CBBB700

Q38409715-0EC19464-F829-448B-9C92-ADC93F9401F8

Q38409715-230AE89F-E400-4F79-9A9A-E410C83D950D

Q38409715-42EA35BE-E6C8-401D-AD1B-D37840D4D7E4

Q38409715-4554263E-3660-47CB-9667-7428781FC98F

Q38409715-54946602-7CF9-4932-AFEB-A418931838A8

Q38409715-5AD67A88-8E34-4232-AA0A-2E372B0FDB8C

Q38409715-5DD53A3A-D9EB-4F4D-AFD9-A0070A73E258

Q38409715-77F44887-7158-4FBF-BD7E-0A7783CAEC31

Q38409715-7AE04972-2920-4E83-B2CE-D78C0B431585

P2860

Q38409715-0037A7C6-BD6D-4A15-82C4-A0F2115A2128

Q38409715-19E477AA-706F-4FC6-A223-9F5E7FAF93BE

Q38409715-24D1798D-0E0D-4870-B371-FF984C9EC087

Q38409715-26DC337E-7AD2-438A-92AB-BCD00E6BCDC5

Q38409715-28582FFE-B327-4B17-8E91-B559D1E4C5D2

Q38409715-2E625602-FAA8-477D-BE52-B7F5CCF72EF0

Q38409715-308C39CC-4AC3-4481-89A4-32DC5989ACB9

Q38409715-399D946E-4CB6-46F6-B2B4-1CDA8639075F

Q38409715-3CD9F9B5-6609-4A42-AE71-8E477A8922B1

Q38409715-4015EA2C-6056-4DAD-92BF-A9FEB0DF9039

P2888

Q38409715-3CCFFBDE-380B-4EF2-86DA-6E8D74A42EA9

P304

Q38409715-3065C498-B44A-4117-B73B-F9295BEDF3FC

P31

Q38409715-A2BC1D0E-11A5-44F6-8DBD-E0979E8A5E20

P356

Q38409715-EABBBF8E-E273-4D62-98AE-739B48D2EFA6

P433

Q38409715-AAA434B1-530B-4C7E-BAFB-83DD7CE20545

P478

Q38409715-62C561A4-C95E-44F2-9998-7D5596AF3297

P50

Q38409715-4109EB0D-E40E-40E6-B14A-C8545F789A49

P577

Q38409715-80CBBEE2-3F69-4DF5-A0E1-CAD6EC69EDD6

P698

Q38409715-0A6C0DB6-F6FF-4DFA-AEB1-0E4F489A7FDC

P932

Q38409715-44269CEE-B9CD-4DE9-98D7-2C030FFA5AD1

P356

S13311-016-0442-6

P1433

Neurotherapeutics

P1476

Tocilizumab in Autoimmune Ence ...... An Institutional Cohort Study

@en

P2093

Han Sang Lee

http://www.w3.org/2001/XMLSchema#string

Jangsup Moon

http://www.w3.org/2001/XMLSchema#string

Jin-Sun Jun

http://www.w3.org/2001/XMLSchema#string

Jung-Ah Lim

http://www.w3.org/2001/XMLSchema#string

Jung-Ick Byun

http://www.w3.org/2001/XMLSchema#string

Keon-Joo Lee

http://www.w3.org/2001/XMLSchema#string

Keun-Hwa Jung

http://www.w3.org/2001/XMLSchema#string

Ki-Young Jung

http://www.w3.org/2001/XMLSchema#string

Kon Chu

http://www.w3.org/2001/XMLSchema#string

Kyung-Il Park

http://www.w3.org/2001/XMLSchema#string

P2860

The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project

Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study

Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms

Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy

Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium

Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens.

Autoimmune encephalitis as differential diagnosis of infectious encephalitis.

The spectrum of acute encephalitis: causes, management, and predictors of outcome.

The spectrum of neuromyelitis optica.

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

P2888

s13311-016-0442-6

P304

824-832

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13311-016-0442-6

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Jun-Sang Sunwoo

P577

2016-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27215218

http://www.w3.org/2001/XMLSchema#string

P932

5081109

http://www.w3.org/2001/XMLSchema#string